You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

7 Items
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Palliative, Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    methotrexate - oral tablets
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Oct 2016
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Oct 2016
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    methotrexate - oral tablets
May 2019
Cancer Type: Breast     
Intent: Palliative, Adjuvant
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019
Cancer Type: Breast     
Intent: Adjuvant, Neoadjuvant, Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Second Line - Metastatic Breast Cancer
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Intermediate Grade, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
ODB - General Benefit
    methotrexate - oral tablets
May 2019